Related references
Note: Only part of the references are listed.Bioactive Cyclization Optimizes the Affinity of a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Peptide Inhibitor
Benjamin J. Tombling et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide-1 Receptor Agonist
John D. Bucheit et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2020)
Salcaprozate sodium (SNAC) enhances permeability of octreotide across isolated rat and human intestinal epithelial mucosae in Ussing chambers
Sarinj Fattah et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2020)
Oral Semaglutide: The First-available Noninjectable Glucagon-like Peptide 1 Receptor Agonist
Jason Powell et al.
CLINICAL THERAPEUTICS (2020)
Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design
Candice Alleyne et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Importance of cynomolgus monkeys in development of monoclonal antibody drugs
Kazuhide Iwasaki et al.
DRUG METABOLISM AND PHARMACOKINETICS (2019)
PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDL-Cholesterol
Yan Wang et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2019)
Recent advances in developing PCSK9 inhibitors for lipid-lowering therapy
Antonio Lavecchia et al.
FUTURE MEDICINAL CHEMISTRY (2019)
Labelled chemical probes for demonstrating direct target engagement in living systems
Hugues Prevet et al.
FUTURE MEDICINAL CHEMISTRY (2019)
Labrasol® is an efficacious intestinal permeation enhancer across rat intestine: Ex vivo and in vivo rat studies
Fiona McCartney et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Assessing the Utility of In Vitro Screening Tools for Predicting Bio-Performance of Oral Peptide Delivery
Prajakta Gadgil et al.
PHARMACEUTICAL RESEARCH (2019)
Small molecules as inhibitors of PCSK9: Current status and future challenges
Shengtao Xu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents
Allyn T. Londregan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Labrasol® and Salts of Medium-Chain Fatty Acids Can Be Combined in Low Concentrations to Increase the Permeability of a Macromolecule Marker Across Isolated Rat Intestinal Mucosae
Joanne Heade et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2018)
Small Molecule Inhibitors of the PCSK9 center dot LDLR Interaction
Jam Taechalertpaisarn et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2018)
Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists
Yingnan Zhang et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2017)
Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists
Yingnan Zhang et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2017)
Disrupting the PCSK9/LDLR protein-protein interaction by an imidazole-based minimalist peptidomimetic
Mattia Stucchi et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2016)
A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab
Marian McDonagh et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2016)
PCSK9: A Key Modulator of Cardiovascular Health
Nabil G. Seidah et al.
CIRCULATION RESEARCH (2014)
Identification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein Receptor
Yingnan Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Evaluating the Role of Macrocycles in the Susceptibility of Hepatitis C Virus NS3/4A Protease Inhibitors to Drug Resistance
Akbar Ali et al.
ACS CHEMICAL BIOLOGY (2013)
Determining target engagement in living systems
Gabriel M. Simon et al.
NATURE CHEMICAL BIOLOGY (2013)
Proprotein Convertase Substilisin/Kexin Type 9 Antagonism Reduces Low-Density Lipoprotein Cholesterol in Statin-Treated Hypercholesterolemic Nonhuman Primates
Hong Liang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Overview of the CCP4 suite and current developments
Martyn D. Winn et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2011)
Clinical Importance of OATP1B1 and OATP1B3 in Drug-Drug Interactions
Yoshihisa Shitara
DRUG METABOLISM AND PHARMACOKINETICS (2011)
Features and development of Coot
P. Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2010)
Genetic and Metabolic Determinants of Plasma PCSK9 Levels
Susan G. Lakoski et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
Joyce C. Y. Chan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Automated ligand placement and refinement with a combined force field and shape potential
S. Wlodek et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2006)
Share Paper
